Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.48 EUR
−438.45 M EUR
681.15 M EUR
158.19 M
About Ionis Pharmaceuticals, Inc.
Sector
Industry
CEO
Brett P. Monia
Website
Headquarters
Carlsbad
Founded
1989
ISIN
US4622221004
FIGI
BBG000FHW679
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
IONS5397611
Ionis Pharmaceuticals, Inc. 0.0% 01-APR-2026Yield to maturity
—
Maturity date
Apr 1, 2026
IONS5835891
Ionis Pharmaceuticals, Inc. 1.75% 15-JUN-2028Yield to maturity
—
Maturity date
Jun 15, 2028
See all ISI bonds
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Ionis Pharmaceuticals, Inc. stocks are traded under the ticker ISI.
We've gathered analysts' opinions on Ionis Pharmaceuticals, Inc. future price: according to them, ISI price has a max estimate of 82.46 EUR and a min estimate of 39.51 EUR. Watch ISI chart and read a more detailed Ionis Pharmaceuticals, Inc. stock forecast: see what analysts think of Ionis Pharmaceuticals, Inc. and suggest that you do with its stocks.
Yes, you can track Ionis Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Ionis Pharmaceuticals, Inc. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
ISI earnings for the last quarter are 0.59 EUR per share, whereas the estimation was −0.08 EUR resulting in a 868.38% surprise. The estimated earnings for the next quarter are −1.04 EUR per share. See more details about Ionis Pharmaceuticals, Inc. earnings.
Ionis Pharmaceuticals, Inc. revenue for the last quarter amounts to 383.70 M EUR, despite the estimated figure of 253.23 M EUR. In the next quarter, revenue is expected to reach 111.34 M EUR.
ISI net income for the last quarter is 104.88 M EUR, while the quarter before that showed −135.82 M EUR of net income which accounts for 177.22% change. Track more Ionis Pharmaceuticals, Inc. financial stats to get the full picture.
No, ISI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 17, 2025, the company has 1.07 K employees. See our rating of the largest employees — is Ionis Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ionis Pharmaceuticals, Inc. EBITDA is −207.21 M EUR, and current EBITDA margin is −64.26%. See more stats in Ionis Pharmaceuticals, Inc. financial statements.
Like other stocks, ISI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ionis Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.